[Resiquimod (R848) has more stronger immune adjuvantivity than other tested TLR agonists]

Area of Science:

• Immunology
• Vaccinology
• Adjuvant research

Background:

• Toll-like receptors (TLRs) are crucial in innate immunity and vaccine adjuvant development.
• Characterizing Th1 immune responses is vital for effective vaccine design.

Purpose of the Study:

• To compare the efficacy of common commercial Toll-like receptor (TLR) agonists in inducing Th1 immune responses.
• To evaluate the in vivo and ex vivo effects of TLR agonists as adjuvants.

Main Methods:

• In vitro stimulation of dendritic cells (DCs) with TLR agonists (poly(I:C), MPLA, R848, CpG-C) and IL-12 measurement via ELISA.
• Flow cytometry analysis of DC, NK, and T cell populations in draining lymph nodes post-immunization.
• Measurement of anti-ovalbumin (OVA) IgG2a serum concentrations via ELISA.

Main Results:

• CpG-C and R848 significantly induced IL-12 production from DCs in vitro.
• R848 demonstrated superior adjuvant activity, recruiting DCs and NK cells, and promoting CD4+/CD8+ T cell proliferation in vivo.
• R848 significantly increased specific anti-OVA IgG2a production.

Conclusions:

• Resiquimod (R848) is the most potent Th1-promoting adjuvant among the tested TLR agonists.
• R848 shows promise for enhancing Th1-biased immune responses in vaccine applications.